MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents

Magnetic Resonance Imaging

Volumn 22, Issue 6, 2004, Pages 843-850

  Funovics, Martin A ^a   Kapeller, Barbara ^a   Hoeller, Christoph ^b   Su, Henry S ^c   Kunstfeld, Rainer ^b   Puig, Stephan ^a   Macfelda, Karin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Iron oxide nanoparticles; Molecular imaging; MRI; Tumor surface antigens

Indexed keywords

ANTIBODY CONJUGATE; CONTRAST MEDIUM; DEXTRAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATIN; IRON; MEMBRANE ANTIGEN; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; PROTEOGLYCAN; SULFATE; TUMOR ANTIGEN; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CELL; CELL CULTURE; CELL LINE; CELL MEMBRANE; CELL SUSPENSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MELANOMA CELL; MEMBRANE BINDING; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECIPITATION; PRIORITY JOURNAL; SPECTROFLUOROMETRY; TRANSMISSION ELECTRON MICROSCOPY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MAGNETIC RESONANCE IMAGING; MELANOMA; MICROSCOPY, ELECTRON; PROTEOGLYCANS; RECEPTOR, ERBB-2;

EID: 3242691732     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2004.01.050     Document Type: Article

References (39)

1. Cerdan S., Lotscher H.R., Kunnecke B., Seelig J. Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn Reson Med. 12:1989;151-163
2. Tung C.H., Lin Y., Moon W.K., Weissleder R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem. 3:2002;784-786
3. Tung C.H., Mahmood U., Bredow S., Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60:2000;4953-4958
4. Bremer C., Bredow S., Mahmood U., Weissleder R., Tung C.H. Optical imaging of matrix metalloproteinase-2 activity in tumors feasibility study in a mouse model. Radiology. 221:2001;523-529
5. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects seeing fundamental biological processes in a new light. Genes Dev. 17:2003;545-580
6. Mahmood U., Tung C.H., Tang Y., Weissleder R. Feasibility of in vivo multichannel optical imaging of gene expression experimental study in mice. Radiology. 224:2002;446-451
7. Ntziachristos V., Tung C.H., Bremer C., Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 8:2002;757-760
8. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 9:2003;123-128
9. Ntziachristos V., Chance B. Accuracy limits in the determination of absolute optical properties using time-resolved NIR spectroscopy. Med Phys. 28:2001;1115-1124
10. Gohr-Rosenthal S., Schmitt-Willich H., Ebert W., Conrad J. The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging. Invest Radiol. 28:1993;789-795
11. Curtet C., Bourgoin C., Bohy J., et al. Gd-25 DTPA-MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse preliminary studies. Int J Cancer Suppl. 2:1988;126-132
12. Khaw B.A., Mattis J.A., Melincoff G., Strauss H.W., Gold H.K., Haber E. Monoclonal antibody to cardiac myosin imaging of experimental myocardial infarction. Hybridoma. 3:1984;11-23
13. Konda S.D., Aref M., Wang S., Brechbiel M., Wiener E.C. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA. 12:2001;104-113
14. Artemov D., Mori N., Ravi R., Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 63:2003;2723-2727
15. Subramanian N., Subramanian S., Adiga P.R. Antigenic similarities among biotin-binding proteins. Biochem Mol Biol Int. 40:1996;663-670
16. Weissleder R., Elizondo G., Wittenberg J., Rabito C.A., Bengele H.H., Josephson L. Ultrasmall superparamagnetic iron oxide characterization of a new class of contrast agents for MR imaging. Radiology. 175:1990;489-493
17. Reimer P., Weissleder R., Wittenberg J., Brady T.J. Receptor-directed contrast agents for MR imaging preclinical evaluation with affinity assays. Radiology. 182:1992;565-569
18. Weissleder R., Lee A.S., Khaw B.A., Shen T., Brady T.J. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct MR antibody imaging. Radiology. 182:1992;381-385
19. Kresse M., Wagner S., Pfefferer D., Lawaczeck R., Elste V., Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med. 40:1998;236-242
20. Kang H.W., Josephson L., Petrovsky A., Weissleder R., Bogdanov A. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem. 13:2002;122-127
21. Artemov D., Mori N., Okollie B., Bhujwalla Z.M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 49:2003;403-408
22. Shahbazi-Gahrouei D., Rizvi S.M., Williams M.A., Allen B.J. In vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents. Australas Phys Eng Sci Med. 25:2002;31-38
23. Sadana A., Vo-Dinh T. Antibody-antigen binding kinetics. A model for multivalency antibodies for large antigen systems. Appl Biochem Biotechnol. 67:1997;1-22
24. Benz C.C., Scott G.K., Santos G.F., Smith H.S. Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst. 81:1989;1704-1709
25. Nagelhus T.A., Rofstad E.K. Expression of the chondroitin sulphate proteoglycan molecular complex in six human melanoma xenograft lines studied by flow cytometry and immunohistochemistry. Melanoma Res. 3:1993;187-194
26. Shen T., Weissleder R., Papisov M., Bogdanov A., Brady T.J. Monocrystalline iron oxide nanocompounds (MION) physicochemical properties. Magn Reson Med. 29:1993;599-604
27. Lind K., Kresse M., Debus N.P., Muller R.H. A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphography comparison of physicochemical properties and the in vivo behaviour. J Drug Target. 10:2002;221-230
28. Murray M.C., Bhavanandan V.P., Davidson E.A., Reinhold V. Modification of sialyl residues of glycoconjugates by reductive amination. Characterization of the modified sialic acids. Carbohydr Res. 186:1989;255-265
29. Schwendener R.A., Trub T., Schott H., et al. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy. Biochim Biophys Acta. 1026:1990;69-79
30. Weissleder R., Lee A.S., Fischman A.J., et al. Polyclonal human immunoglobulin G labeled with polymeric iron oxide antibody MR imaging. Radiology. 181:1991;245-249
31. Wong W.M. Drug update trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract. 7:1999;48-50
32. Bowen C.V., Zhang X., Saab G., Gareau P.J., Rutt B.K. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med. 48:2002;52-61
33. Shockley T.R., Lin K., Nagy J.A., Tompkins R.G., Yarmush M.L., Dvorak H.F. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res. 52:1992;367-376
34. Fearon D.T., Kaneko I., Thomson G.G. Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J Exp Med. 153:1981;1615-1628
35. Josephson L., Groman E.V., Menz E., Lewis J.M., Bengele H. A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent. Magn Reson Imaging. 8:1990;637-646
36. Tiefenauer L.X., Kuhne G., Andres R.Y. Antibody-magnetite nanoparticles in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug Chem. 4:1993;347-352
37. Okon E., Pouliquen D., Okon P., et al. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest. 71:1994;895-903
38. Go K.G., Bulte J.W., de Ley L., et al. Our approach towards developing a specific tumour-targeted MRI contrast agent for the brain. Eur J Radiol. 16:1993;171-175
39. Renkin E.M., Curry F.E. Endothelial permeability pathways and modulations. Ann N Y Acad Sci. 401:1982;248-259